- A new website helps pain patients to better express and explain how
their pain feels like
AACHEN, Germany, Oct. 8, 2013 /CNW/ - Pain can appear in many forms and
affects people in different ways. One kind of long-lasting or chronic
pain results from a damaged nerve that sends incorrect pain messages
to the brain. This pain is called neuropathic pain or nerve pain.
Over 26 million people worldwide suffer from neuropathic pain but only 40-60% of patients achieve adequate pain relief.
The majority, approximately 60%, of neuropathic pain is localised (localised neuropathic pain, LNP) and is often described as a burning,
shooting, lancinating, electric shock like. But more frequently patients are trying to describe their pain in their
own words by using their individual, often very pictographic language.
A correct and early diagnose is crucial to find the right treatment.
Therefore patients need to describe their symptoms in as much detail as
possible to their doctor.
At the new website http://www.mypainfeelslike.com patients find a questionnaire that helps them to describe in detail how
their pain feels like, how it affects their life and where the pain is
"My pain feels like…" has been developed by Grünenthal GmbH in
collaboration with the Montescano Pain School, Italy. For more
information please visit http://www.grunenthal.com
The Grünenthal Group is an independent, family-owned, international
research-based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective is to
become the most patient-centric company and thus to be a leader in
therapy innovation. Grünenthal is one of the last remaining five
research-oriented pharmaceutical companies with headquarters in Germany
which sustainably invests in research and development. The research and
development costs amounted to a preliminary of about 26 percent of
revenues in 2012. Grünenthal's research and development strategy
concentrates on selected fields of therapy and state-of-the-art
technologies. We are intensely focused on discovering new ways to treat
pain better and more effectively, with fewer side-effects than current
therapies. Altogether, the Grünenthal Group has affiliates in
26 countries worldwide. Grünenthal products are sold in more than
155 countries and today approx. 4,400 employees are working for the
Grünenthal Group worldwide. In 2012, Grünenthal achieved preliminary
revenues of € 973 mn. More information: http://www.grunenthal.com.
1 Pal M et al (2009). Vanilloid receptor antagonists: emerging class of
novel anti-inflammatory agents for pain management. Curr Pharm Des
2 Dworkin RH, O'Connor AB, Backonja M, et al (2007). Pharmacologic
management of neuropathic pain: evidence-based recommendations.
3 Mick G et al (2012). What is localised neuropathic pain? A first
proposal to characterise and define a widely used term. Pain manage
4 Woolf C et al (1999). Neuropathic pain: aetiology, symptoms,
mechanisms, and management. Lancet; 353:1959-64
SOURCE: Grunenthal GmbH
For further information:
Contact: Jeanette Hübsch, Grünenthal Europe & Australia
Phone: +49-241-569-1487, email: firstname.lastname@example.org